低酸素/再酸素化後心筋細胞におけるミトコンドリア膜電位を測定するためのフロー フローサイトメトリーを用いたアッセイ

Executive Industry Relevance

Assessing mitochondrial membrane potential (MMP) is critical for evaluating cardioprotective strategies in ischemia-reperfusion injury models. This flow cytometry-based JC-1 assay provides a quantitative, high-throughput readout of mitochondrial depolarization in human cardiac myocytes, enabling mechanistic de-risking of therapeutic candidates targeting reperfusion injury. The method supports target validation by linking MMP changes to mitochondrial permeability transition pore (mPTP) opening, a key event in cardiomyocyte death.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Measures MMP as a functional readout of mitochondrial health and mPTP opening in disease-relevant human cardiac myocytes.
• Operational Value: Enables interrogation of therapeutic hypotheses regarding cytoprotective agents under hypoxia/reoxygenation stress.
• Predictive Value: Supports target confidence by correlating MMP preservation with reduced apoptosis, as demonstrated by Annexin PI ratio.

Screening & Assay Development

• Scientific Value: JC-1’s red/green fluorescence ratio provides a ratiometric, mitochondria-specific readout independent of cell size or granularity.
• Operational Value: Low material requirements and compatibility with standard flow cytometry platforms support assay scalability and reproducibility.
• Screening Readiness: Enables rapid evaluation of compound libraries for effects on MMP in a physiologically relevant human cell model.

Translational & Preclinical Research

• Scientific Value: Uses human cardiac myocytes to enhance translational relevance over rodent models in ischemia-reperfusion studies.
• Operational Value: Standardized hypoxia/reoxygenation protocol allows consistent induction of mitochondrial depolarization for compound testing.
• Predictive Value: Facilitates go/no-go decisions by linking MMP protection to functional outcomes like reduced apoptosis.

Pipeline & Workflow Integration

The assay fits within the early discovery continuum, supporting target validation and lead identification by providing mechanistic insights into mitochondrial dysfunction in cardiovascular disease models.

• Discovery Biology: Enables hypothesis testing of MMP as a biomarker of mPTP activation and reperfusion injury severity.
• Screening: Delivers quantitative, normalized fluorescence ratio data suitable for hit selection and dose-response profiling.
• Analytics: Generates red/green intensity ratio metrics that allow statistical comparison across treatment groups.
• Translational Research: Uses human-derived cells to improve predictive confidence for preclinical advancement.
• Enterprise Reuse: Protocol can be adapted across cardiotoxicity and cardioprotection screening campaigns.

Operational & Enterprise Impact

• Scientific Value: Provides mechanistic insight into mitochondrial depolarization as a convergent point of reperfusion injury pathways.
• Operational Value: Minimizes variability by normalizing MMP readout to mitochondrial content via ratiometric JC-1 detection.
• Strategic Value: Improves capital efficiency by enabling early identification of compounds that preserve MMP and reduce apoptotic commitment.
• Portfolio Impact: Supports risk-adjusted prioritization of candidates demonstrating MMP stabilization in human cardiac myocytes.

Implementation Considerations

• Requires expertise in primary human cardiac myocyte culture and hypoxia/reoxygenation modeling.
• Dependent on flow cytometry with FITC and PE detection channels and logarithmic fluorescence scaling.
• Necessitates strict temperature control during JC-1 staining to preserve mitochondrial membrane potential integrity.
• Requires standardization of hypoxia duration and reoxygenation timing across experimental groups.
• Limited to adherent cell types amenable to trypsinization and washing without loss of viability.

Biopharma FAQs